Uroplasty (UPI +4.8%) says a class action lawsuits filed against the company alleging possible violations of federal securities laws in relation to the delayed filing of its 10K earlier this year has been dismissed. No payment or consideration of any kind was made by URI in connection with these lawsuits.
Uroplasty (UPI +17%) pops today after saying Medicare administrative contractor Novitas Solutions has expanded coverage for posterior tibial nerve stimulation using the company's Urgent PC neuromodulation system to treat overactive bladder and associated symptoms.
The increased coverage includes additional diagnostic codes as well as expansion of on-going therapy from 12 months to up to two years.
The company also reported FQ1 earnings last night that largely trailed analysts forecasts. (PR)